Ensymm successfully executed a semi-commercial pilot trial for the deacetylation of chitin to chitosan using an ultrasonic-assisted process, achieving a high degree of deacetylation (DD). This innovative method replaces conventional high-temperature alkaline cooking, significantly improving process efficiency, energy consumption, and environmental performance. Ensymm now offers a fully integrated, industrial-scale chitosan production process with zero hazardous waste output.

Ensymm conducted a conceptual techno-financial feasibility study for a blood plasma fractionation facility in Iraq, in collaboration with a specialized EU-based EPC partner.

Ensymm was awarded a contract to inspect and audit a chitosan production facility in Cairo, Egypt, delivering a comprehensive GAP analysis, including recommendations for process optimization and QA/QC upgrades.

Dr. Pedram Dehdari delivered a guest lecture at the IEEE Summit in Kigali, Rwanda on “Entrepreneurs and Start-up Surviving Strategy in the Business Jungle”. Reference: https://www.instagram.com/p/DJ7QVKIOM46/

Ensymm was appointed as project advisor to support a Libyan investor group in evaluating the establishment of an IV fluid production facility in Tripoli, Libya.

Ensymm was commissioned to prepare a project consultancy dossier for the evaluation and validation of a techno-financial feasibility study for an oncological injectable production facility in the UAE.

A sugar industry client in Pakistan successfully completed the installation of a 5,000 MT/year invert sugar (glucose–fructose syrup) plant in Lahore, utilizing Ensymm’s enzymatic process technology.

Ensymm expanded its enzyme supply portfolio, delivering:

Lactase powder for capsule manufacturing/Liquid lactase (ready-mix) for lactase drop production to clients in the Netherlands, Czech Republic, and Greece.